A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Peer Review reports

Original Submission
6 Aug 2020	Submitted	Original manuscript
26 Aug 2020	Reviewed	Reviewer Report - Alexander Gough
27 Sep 2020	Reviewed	Reviewer Report - Todd Rice
10 Oct 2020	Author responded	Author comments - Timothy Devos
Resubmission - Version 2
10 Oct 2020	Submitted	Manuscript version 2
31 Oct 2020	Reviewed	Reviewer Report - Todd Rice
4 Nov 2020	Reviewed	Reviewer Report - Alexander Gough
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
4 Nov 2020	Editorially accepted
27 Nov 2020	Article published	10.1186/s13063-020-04876-0

Back to article page